Eli Lilly Acquires Engage Bio for Up to $202 Million
Eli Lilly has acquired Engage Bio (engagebio.com), a preclinical biotech developing non-viral DNA delivery technology, for up to $202 million in cash. Engage Bio went through Y Combinator's W22 batch, with seed investors including Pioneer Fund.
Engage Bio built what it calls the Tethosome platform: a system that pairs engineered DNA payloads with lipid nanoparticle delivery and an mRNA-encoded proprietary protein. Using LNP technology, the platform delivers therapeutic DNA alongside an mRNA encoding a proprietary Tethosome protein that localizes DNA to the nucleus, increasing expression by over 100-fold.
The platform is also designed to evade immune sensors that detect foreign DNA and can cause dangerous immune reactions.
The core problem Engage set out to solve is that non-viral DNA delivery has historically been held back by two things: potency and toxicity. Viral vectors like AAV can deliver genes effectively but come with manufacturing complexity, immune responses, and limits on redosing. Engage's Tethosome platform enables durable, re-dosable gene expression without viral vectors.
"With a lean organization and modest seed funding, I am incredibly proud of the rapid progress Engage has made toward a new class of genetic medicines. This is a testament to what a nimble, passionate team can achieve with the tools of synthetic biology," said Will Olsen, Co-Founder and CEO of Engage.
Olsen co-founded the company after serving as VP of mRNA Therapeutic Development at Stanford spinout Rejuvenation Technologies. He previously co-founded diagnostic startup Luminist Labs in 2015, which was acquired in 2019. The company was founded in 2021.
"Will and the Engage Bio team are exactly the kind of founders we aim to back at Pioneer: exceptional scientists solving a problem the field had largely written off as too hard. A small team doing big science. We were excited to support the company early and it's been rewarding to see that vision validated through this outcome with Eli Lilly."
Dave Messina, General Partner of Pioneer's Future of Health Fund
The acquisition fits neatly into Lilly's aggressive push into genetic medicines over the past year. Lilly has acquired Verve Therapeutics and Orna Therapeutics, each taking different approaches to developing in vivo genetic medicines. The pharma giant also bought Adverum Biotechnologies for its intravitreal gene therapy pipeline, acquired Kelonia Therapeutics for $3.25 billion upfront for its in vivo cell therapy platform, and struck a deal with Seamless Therapeutics worth over $1.12 billion in total payouts for gene editing treatments targeting hearing loss. Engage Bio adds a non-viral DNA approach to that growing toolkit.
Engage Bio was also awarded a grant from the Gates Foundation to extend the reach of its non-viral DNA platform, and completed a collaborative research study with a top-10 global pharma partner prior to the acquisition.
The $202 million deal is structured as an upfront cash payment with additional payouts contingent on the achievement of specified development milestones, a common structure for preclinical-stage acquisitions.
For a seed-funded, 10-person company to get acquired by one of the world's largest pharmaceutical companies is a notable outcome. Olsen framed it as the beginning of a new phase rather than an ending: "We are excited to begin our next chapter with Lilly, which has demonstrated unmatched speed and a uniquely forward-thinking approach to genetic medicine."